Alun Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alun Davies has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Noni Mumba
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
9 shared publications - Dorcas Kamuya
Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi
6 shared publications - Janet Seeley
Africa Health Research Institute
5 shared publications Grace Mwango
4 shared publications- Sassy Molyneux
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
4 shared publications Abigail Harrison
Brown University Providence Rhode Island USA
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (S5) , e70192
Adaptation and Evaluation of a Multi‐Component School‐Based Sexual Reproductive Health Intervention Safer Choices Programme in Rural KwaZulu‐Natal, South Africa – A Process Evaluation
Introduction: We co‐adapted and evaluated a multi‐component whole‐school health‐promotion Safer Choices programme to improve sexual and reproductive health (SRH) and uptake of HIV‐prevention among learners in rural uMkhanyakude district, KwaZulu‐Natal, South Africa. Methods: From January 2023 to June 2025, we used the Framework for Reporting Adaptations and Modifications‐Enhanced (FRAME) to guide and document Safer Choices adaptations. We used participatory qualitative approaches and a process evaluation to assess intervention acceptability and feasibility. Co‐adapting involved a 3‐day workshop with 16 learners aged 15–19 (Grade 9–10), four discussions with school leadership and two focus group discussions (FGDs) with parents/guardians, to understand the context and social validity of the programme. Intervention acceptability was assessed through five in‐depth interviews with teachers/school leadership and three with peer leaders, two workshops with intervention and clinical delivery teams, two FGDs with community members and five with learners. Interactions were audio‐recorded, transcribed and analysed using thematic analysis. Results: Schools were described as learning spaces providing opportunities for health promotion through health and well‐being lessons. Teachers and parents/guardians noted a need for Safer Choices to provide SRH/HIV services in schools, as most learners were already sexually active. Provision of mobile SRH/HIV services in schools was perceived to be feasible if negotiated with the school and HIV‐status neutral services were provided to minimize stigma. Adaptations to Safer Choices were focused on optimizing intervention delivery or emphasizing social validity of the programme. During implementation of Safer Choices, myths and misconceptions around HIV and pregnancy were addressed. Challenges such as no electricity and large classes made it difficult to deliver Safer Choices. Peer navigators (lay youth‐workers) were engaged to help deliver the intervention. Conclusions: In a context of high sexual risk and vulnerability, it was feasible to co‐adapt and deliver the Safer Choices programme, which provided accurate and accessible SRH information and services to address adolescent SRH needs of learners in our rural schools. Adaptation challenges included balancing fidelity to intervention with both the “real‐world” context and the practicality of peer navigators supporting intervention delivery. These results suggest that optimizing the impact necessitates appropriately resourcing school‐based interventions to address the challenges of programming in rural settings.
- 8 October 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (S5) , e70192
Open AccessAdaptation and Evaluation of a Multi‐Component School‐Based Sexual Reproductive Health Intervention Safer Choices Programme in Rural KwaZulu‐Natal, South Africa – A Process Evaluation
Introduction: We co‐adapted and evaluated a multi‐component whole‐school health‐promotion Safer Choices programme to improve sexual and reproductive health (SRH) and uptake of HIV‐prevention among learners in rural uMkhanyakude district, KwaZulu‐Natal, South Africa. Methods: From January 2023 to June 2025, we used the Framework for Reporting Adaptations and Modifications‐Enhanced (FRAME) to guide and document Safer Choices adaptations. We used participatory qualitative approaches and a process evaluation to assess intervention acceptability and feasibility. Co‐adapting involved a 3‐day workshop with 16 learners aged 15–19 (Grade 9–10), four discussions with school leadership and two focus group discussions (FGDs) with parents/guardians, to understand the context and social validity of the programme. Intervention acceptability was assessed through five in‐depth interviews with teachers/school leadership and three with peer leaders, two workshops with intervention and clinical delivery teams, two FGDs with community members and five with learners. Interactions were audio‐recorded, transcribed and analysed using thematic analysis. Results: Schools were described as learning spaces providing opportunities for health promotion through health and well‐being lessons. Teachers and parents/guardians noted a need for Safer Choices to provide SRH/HIV services in schools, as most learners were already sexually active. Provision of mobile SRH/HIV services in schools was perceived to be feasible if negotiated with the school and HIV‐status neutral services were provided to minimize stigma. Adaptations to Safer Choices were focused on optimizing intervention delivery or emphasizing social validity of the programme. During implementation of Safer Choices, myths and misconceptions around HIV and pregnancy were addressed. Challenges such as no electricity and large classes made it difficult to deliver Safer Choices. Peer navigators (lay youth‐workers) were engaged to help deliver the intervention. Conclusions: In a context of high sexual risk and vulnerability, it was feasible to co‐adapt and deliver the Safer Choices programme, which provided accurate and accessible SRH information and services to address adolescent SRH needs of learners in our rural schools. Adaptation challenges included balancing fidelity to intervention with both the “real‐world” context and the practicality of peer navigators supporting intervention delivery. These results suggest that optimizing the impact necessitates appropriately resourcing school‐based interventions to address the challenges of programming in rural settings.
- Open Access
- 17 July 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 153
Developing and pretesting a sexual reproductive health (SRH) school health promotion intervention (Safer Choices program) in rural South Africa: Study Protocol
Background Young people remain at highest risk of HIV, sexually transmitted infections (STIs) and early pregnancy. The WHO Global School Health Initiative acknowledges the opportunity to promote effective health interventions within the sustainable infrastructure of schools. Safer Choices is a school-based multiple-component whole-school intervention effective in reducing sexual risk behaviours and preventing HIV, STIs and pregnancy among high-school learners. The overall aim of this study is to adapt and evaluate a Safer Choices program to improve uptake of sexual reproductive health (SRH) and HIV-prevention amongst 15-19-year-old learners in rural KwaZulu-Natal, South Africa. Methods This study will use a mixed-method study design guided by the MRC-framework for development and evaluation of complex interventions. We will use the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) to document modifications to Safer Choices. The study will be conducted across six purposively selected high schools in uMkhanyakude district. The study will be divided into three work-packages (WP): WP1 to adapt and refine Safer Choices to context using participatory research methods; WP2 to pilot and assess acceptability and feasibility of the adapted intervention followed by a process evaluation to understand reach, uptake, acceptability and feasibility of intervention. We will conduct pre/post intervention surveys with 390 randomly selected learners aged 15-19 to measure exposure, satisfaction, changes in self-reported SRH and HIV-risk behaviours. WP3 will include collection of exploratory data on the effect of the intervention on improving resilience and uptake of HIV-prevention and SRH services 60-days post-intervention delivery. Discussion This study protocol paper reports the details of our design for adaptation and evaluation of Safer Choices, with the aim of informing efforts elsewhere and scale-up of this evidence-based intervention. Integrating Safer Choices with SRH and HIV services will likely amplify its effectiveness, offering a holistic framework that addresses the multifaceted nature of HIV prevention.
- 17 July 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 153
Open AccessDeveloping and pretesting a sexual reproductive health (SRH) school health promotion intervention (Safer Choices program) in rural South Africa: Study Protocol
Background Young people remain at highest risk of HIV, sexually transmitted infections (STIs) and early pregnancy. The WHO Global School Health Initiative acknowledges the opportunity to promote effective health interventions within the sustainable infrastructure of schools. Safer Choices is a school-based multiple-component whole-school intervention effective in reducing sexual risk behaviours and preventing HIV, STIs and pregnancy among high-school learners. The overall aim of this study is to adapt and evaluate a Safer Choices program to improve uptake of sexual reproductive health (SRH) and HIV-prevention amongst 15-19-year-old learners in rural KwaZulu-Natal, South Africa. Methods This study will use a mixed-method study design guided by the MRC-framework for development and evaluation of complex interventions. We will use the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) to document modifications to Safer Choices. The study will be conducted across six purposively selected high schools in uMkhanyakude district. The study will be divided into three work-packages (WP): WP1 to adapt and refine Safer Choices to context using participatory research methods; WP2 to pilot and assess acceptability and feasibility of the adapted intervention followed by a process evaluation to understand reach, uptake, acceptability and feasibility of intervention. We will conduct pre/post intervention surveys with 390 randomly selected learners aged 15-19 to measure exposure, satisfaction, changes in self-reported SRH and HIV-risk behaviours. WP3 will include collection of exploratory data on the effect of the intervention on improving resilience and uptake of HIV-prevention and SRH services 60-days post-intervention delivery. Discussion This study protocol paper reports the details of our design for adaptation and evaluation of Safer Choices, with the aim of informing efforts elsewhere and scale-up of this evidence-based intervention. Integrating Safer Choices with SRH and HIV services will likely amplify its effectiveness, offering a holistic framework that addresses the multifaceted nature of HIV prevention.
- Open Access
- 26 March 2026
- Published by Wiley in Health Expectations
- Vol. 29 (2) , e70616
The ‘Public’ in Public Involvement: A Call to Centre Frontline Staff Voices in Health Workforce Research
Public involvement, or patient and public involvement and engagement (PPIE), is widely embedded in health and care research and is valued for its moral, ethical, and methodological contributions. However, its application in workforce research raises important questions about the voices that might be missing from the ‘public’ when research's primary object of inquiry is healthcare staff, organisations, and systems, rather than patients and service users. This viewpoint explores tensions arising from the extension of standardised public involvement requirements, which were originally developed for research where patients and service users are the primary target of focus, into workforce‐focused studies. We argue that while patient and public perspectives remain crucial, the lived experience and voices of frontline staff are often under‐recognised in existing involvement frameworks, including those used in NIHR domestic programmes, as they are not fully accommodated within either public involvement or stakeholder engagement activities. We therefore call for greater clarity, flexibility, and, where appropriate, expansion in how public involvement is conceptualised and operationalised in workforce research, to better centre the voices of frontline staff. Rather than offering definitive solutions, we invite debate and future research on how public involvement can be made more meaningful, proportionate, and fit‐for‐purpose in health and care workforce research. Patient or Public Contribution: This viewpoint article is written by researchers in the health and care workforce, PPIE, and community engagement, and a public contributor with interest and experience of involvement in health and care workforce research. We drew on our respective perspectives and experience to shape the framing and arguments presented in this viewpoint.
- 26 March 2026
- Published by Wiley in Health Expectations
- Vol. 29 (2) , e70616
Open AccessThe ‘Public’ in Public Involvement: A Call to Centre Frontline Staff Voices in Health Workforce Research
Public involvement, or patient and public involvement and engagement (PPIE), is widely embedded in health and care research and is valued for its moral, ethical, and methodological contributions. However, its application in workforce research raises important questions about the voices that might be missing from the ‘public’ when research's primary object of inquiry is healthcare staff, organisations, and systems, rather than patients and service users. This viewpoint explores tensions arising from the extension of standardised public involvement requirements, which were originally developed for research where patients and service users are the primary target of focus, into workforce‐focused studies. We argue that while patient and public perspectives remain crucial, the lived experience and voices of frontline staff are often under‐recognised in existing involvement frameworks, including those used in NIHR domestic programmes, as they are not fully accommodated within either public involvement or stakeholder engagement activities. We therefore call for greater clarity, flexibility, and, where appropriate, expansion in how public involvement is conceptualised and operationalised in workforce research, to better centre the voices of frontline staff. Rather than offering definitive solutions, we invite debate and future research on how public involvement can be made more meaningful, proportionate, and fit‐for‐purpose in health and care workforce research. Patient or Public Contribution: This viewpoint article is written by researchers in the health and care workforce, PPIE, and community engagement, and a public contributor with interest and experience of involvement in health and care workforce research. We drew on our respective perspectives and experience to shape the framing and arguments presented in this viewpoint.
- Open Access
- 26 February 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 153
Developing and pretesting a sexual reproductive health (SRH) school health promotion intervention (Safer Choices program) in rural South Africa: Study Protocol
Background Young people remain at highest risk of HIV, sexually transmitted infections (STIs) and early pregnancy. The WHO Global School Health Initiative acknowledges the opportunity to promote effective health interventions within the sustainable infrastructure of schools. Safer Choices is a school-based multiple-component whole-school intervention effective in reducing sexual risk behaviours and preventing HIV, STIs and pregnancy among high-school learners. The overall aim of this study is to adapt and evaluate a Safer Choices program to improve uptake of sexual reproductive health (SRH) and HIV-prevention amongst 15-19-year-old learners in rural KwaZulu-Natal, South Africa. Methods This study will use a mixed-method study design guided by the MRC-framework for development and evaluation of complex interventions. We will use the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) to document modifications to Safer Choices. The study will be conducted across six purposively selected high schools in uMkhanyakude district. The study will be divided into three work-packages (WP): WP1 to adapt and refine Safer Choices to context using participatory research methods; WP2 to pilot and assess acceptability and feasibility of the adapted intervention followed by a process evaluation to understand reach, uptake, acceptability and feasibility of intervention. We will conduct pre/post intervention surveys with 390 randomly selected learners aged 15-19 to measure exposure, satisfaction, changes in self-reported SRH and HIV-risk behaviours. WP3 will include collection of exploratory data on the effect of the intervention on improving resilience and uptake of HIV-prevention and SRH services 60-days post-intervention delivery. Discussion This study protocol paper reports the details of our design for adaptation and evaluation of Safer Choices, with the aim of informing efforts elsewhere and scale-up of this evidence-based intervention. Integrating Safer Choices with SRH and HIV services will likely amplify its effectiveness, offering a holistic framework that addresses the multifaceted nature of HIV prevention.
- 26 February 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 153
Open AccessDeveloping and pretesting a sexual reproductive health (SRH) school health promotion intervention (Safer Choices program) in rural South Africa: Study Protocol
Background Young people remain at highest risk of HIV, sexually transmitted infections (STIs) and early pregnancy. The WHO Global School Health Initiative acknowledges the opportunity to promote effective health interventions within the sustainable infrastructure of schools. Safer Choices is a school-based multiple-component whole-school intervention effective in reducing sexual risk behaviours and preventing HIV, STIs and pregnancy among high-school learners. The overall aim of this study is to adapt and evaluate a Safer Choices program to improve uptake of sexual reproductive health (SRH) and HIV-prevention amongst 15-19-year-old learners in rural KwaZulu-Natal, South Africa. Methods This study will use a mixed-method study design guided by the MRC-framework for development and evaluation of complex interventions. We will use the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) to document modifications to Safer Choices. The study will be conducted across six purposively selected high schools in uMkhanyakude district. The study will be divided into three work-packages (WP): WP1 to adapt and refine Safer Choices to context using participatory research methods; WP2 to pilot and assess acceptability and feasibility of the adapted intervention followed by a process evaluation to understand reach, uptake, acceptability and feasibility of intervention. We will conduct pre/post intervention surveys with 390 randomly selected learners aged 15-19 to measure exposure, satisfaction, changes in self-reported SRH and HIV-risk behaviours. WP3 will include collection of exploratory data on the effect of the intervention on improving resilience and uptake of HIV-prevention and SRH services 60-days post-intervention delivery. Discussion This study protocol paper reports the details of our design for adaptation and evaluation of Safer Choices, with the aim of informing efforts elsewhere and scale-up of this evidence-based intervention. Integrating Safer Choices with SRH and HIV services will likely amplify its effectiveness, offering a holistic framework that addresses the multifaceted nature of HIV prevention.
- Open Access
- 8 March 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 141
Impact of virtual reality on promoting understanding of research in rural Africa: The KEMRI-Wellcome Trust virtual tour of research laboratories
Background Virtual Reality (VR) is poised to transform how science is communicated to the public. There is limited evidence of the use of VR for science education or engagement in sub-Saharan Africa. We produced a virtual reality video tour of the KEMRI-Wellcome Trust Research Programme (KWTRP) laboratories and tested its suitability as an engagement tool for secondary school students. Methods A group of 14 students from various secondary schools, but residents of Kilifi County, situated on the coast of Kenya, were invited for a guided tour of KWTRP laboratories. After that, they were split into three groups to discuss their understanding of the tour and what was relatable to what they were learning in school. The discussion informed the script of a 360 degree video of the KWTRP laboratories. The video was uploaded to the VR headsets and shown to select students (n=59) from three secondary schools in Kilifi County. We administered pre and post survey questionnaires to assess the impact of the virtual tour of the research laboratories. Results Most students reported having never watched videos on laboratory or research before, with few having ever used a virtual reality (VR) headset. After watching the virtual reality video of the laboratory, most students indicated that they found the VR experience good and agreed that it made them feel like they were touring the laboratory in person. They also indicated that they had an increased interest in working in a research laboratory. We observed significant gains in knowledge related to KWTRP among the students after watching the VR video. Conclusions Enabling the public to understand how research is conducted is important for garnering community confidence and scientific support. The virtual reality experience of research laboratories offers a promising tool for science engagement in young adults.
- 8 March 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 141
Open AccessImpact of virtual reality on promoting understanding of research in rural Africa: The KEMRI-Wellcome Trust virtual tour of research laboratories
Background Virtual Reality (VR) is poised to transform how science is communicated to the public. There is limited evidence of the use of VR for science education or engagement in sub-Saharan Africa. We produced a virtual reality video tour of the KEMRI-Wellcome Trust Research Programme (KWTRP) laboratories and tested its suitability as an engagement tool for secondary school students. Methods A group of 14 students from various secondary schools, but residents of Kilifi County, situated on the coast of Kenya, were invited for a guided tour of KWTRP laboratories. After that, they were split into three groups to discuss their understanding of the tour and what was relatable to what they were learning in school. The discussion informed the script of a 360 degree video of the KWTRP laboratories. The video was uploaded to the VR headsets and shown to select students (n=59) from three secondary schools in Kilifi County. We administered pre and post survey questionnaires to assess the impact of the virtual tour of the research laboratories. Results Most students reported having never watched videos on laboratory or research before, with few having ever used a virtual reality (VR) headset. After watching the virtual reality video of the laboratory, most students indicated that they found the VR experience good and agreed that it made them feel like they were touring the laboratory in person. They also indicated that they had an increased interest in working in a research laboratory. We observed significant gains in knowledge related to KWTRP among the students after watching the VR video. Conclusions Enabling the public to understand how research is conducted is important for garnering community confidence and scientific support. The virtual reality experience of research laboratories offers a promising tool for science engagement in young adults.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A108.2-A109
PA-679 Engaging youths on social and ethical issues around bio-banking in Kilifi, Kenya. Use of deliberative consultation workshops
Background There is increasing attention to bio-banking in health research due to its value in providing rapid turnaround of research results. However, bio-banking in Sub-Saharan Africa is still in infancy and is wrought with many ethical and social-cultural challenges. There’s a dearth of research focusing on informed views of young people, who are likely to be the greatest consumers of health research information. At the KEMRI Wellcome Trust Research Programme (KWTRP) with nearly 1.5million biological specimens stored for over 30years, social science research investigated opinions about biobank/ing, and the ethical and social-cultural considerations from diverse stakeholders including youth. Methods One-day deliberative consultation workshop with 44/47 Young Persons Advisory Group members from three secondary schools in Kilifi County. This aimed at informing and seeking opinions of the youth on the ethical and social-cultural issues of biobank/ing. Activities included discussions about DNA, KWTRP biobank tour, plenary and focus group discussions. Topics discussed included views on sample storage, sharing, consent, assent, and benefits of bio-banking. Data was transcribed, translated to English, and analyzed using thematic analysis. Results Participants seemed to understand health research and supported bio-banking due to its associated benefits. They emphasized strict adherence to ethical guidelines on sample sharing, especially confidentiality. They supported initial parental consent for continued storage and sharing of samples collected for research while they were minors. Tracing participants who transit to adults, and recall biases were some of the reasons given for not re-contacting minors to re-affirm consent for continued secondary sample use. They also suggested that assent age should be lowered to 9–16years [as opposed to 13–17 years]. Conclusion Engaging the youth in bio-banking was regarded as an important step. Therefore, with careful considerations, youth can be engaged to demystify health research and bio-banking through well-tailored and suited engagement strategies. Funders: Wellcome Trust, Global Health Bioethics Network and NIH Fogarty.
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A108.2-A109
Open AccessPA-679 Engaging youths on social and ethical issues around bio-banking in Kilifi, Kenya. Use of deliberative consultation workshops
Background There is increasing attention to bio-banking in health research due to its value in providing rapid turnaround of research results. However, bio-banking in Sub-Saharan Africa is still in infancy and is wrought with many ethical and social-cultural challenges. There’s a dearth of research focusing on informed views of young people, who are likely to be the greatest consumers of health research information. At the KEMRI Wellcome Trust Research Programme (KWTRP) with nearly 1.5million biological specimens stored for over 30years, social science research investigated opinions about biobank/ing, and the ethical and social-cultural considerations from diverse stakeholders including youth. Methods One-day deliberative consultation workshop with 44/47 Young Persons Advisory Group members from three secondary schools in Kilifi County. This aimed at informing and seeking opinions of the youth on the ethical and social-cultural issues of biobank/ing. Activities included discussions about DNA, KWTRP biobank tour, plenary and focus group discussions. Topics discussed included views on sample storage, sharing, consent, assent, and benefits of bio-banking. Data was transcribed, translated to English, and analyzed using thematic analysis. Results Participants seemed to understand health research and supported bio-banking due to its associated benefits. They emphasized strict adherence to ethical guidelines on sample sharing, especially confidentiality. They supported initial parental consent for continued storage and sharing of samples collected for research while they were minors. Tracing participants who transit to adults, and recall biases were some of the reasons given for not re-contacting minors to re-affirm consent for continued secondary sample use. They also suggested that assent age should be lowered to 9–16years [as opposed to 13–17 years]. Conclusion Engaging the youth in bio-banking was regarded as an important step. Therefore, with careful considerations, youth can be engaged to demystify health research and bio-banking through well-tailored and suited engagement strategies. Funders: Wellcome Trust, Global Health Bioethics Network and NIH Fogarty.
- Open Access
- 27 November 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Background There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind, randomised, controlled trial among adults in Kenya conducted as part of the early studies assessing vaccine performance in different geographical settings to inform Emergency Use Authorisation. Methods We recruited and randomly assigned (1:1) 400 healthy adults aged ≥18 years in Kenya to receive ChAdOx1 nCoV-19 or control rabies vaccine, each as a two-dose schedule with a 3-month interval. The co-primary outcomes were safety, and immunogenicity assessed using total IgG enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 spike protein 28 days after the second vaccination. Results Between 28th October 2020 and 19th August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n=200) or rabies vaccine (n=200). Local and systemic adverse events were self-limiting and mild or moderate in nature. Three serious adverse events were reported but these were deemed unrelated to vaccination. The geometric mean anti-spike IgG titres 28 days after second dose vaccination were higher in the ChAdOx1 group (2773 ELISA units [EU], 95% CI 2447, 3142) than in the rabies vaccine group (61 EU, 95% CI 45, 81) and persisted over the 12 months follow-up. We did not identify any symptomatic infections or hospital admissions with respiratory illness and so vaccine efficacy against clinically apparent infection could not be measured. Vaccine efficacy against asymptomatic SARS-CoV-2 infection was 38.4% (95% CI -26.8%, 70.1%; p=0.188). Conclusions The safety, immunogenicity and efficacy against asymptomatic infection of ChAdOx1 nCoV-19 among Kenyan adults was similar to that observed elsewhere in the world, but efficacy against symptomatic infection or severe disease could not be measured in this cohort. Pan-African Clinical Trials Registration PACTR202005681895696 (11/05/2020)
- 27 November 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 182
Open AccessSafety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Background There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind, randomised, controlled trial among adults in Kenya conducted as part of the early studies assessing vaccine performance in different geographical settings to inform Emergency Use Authorisation. Methods We recruited and randomly assigned (1:1) 400 healthy adults aged ≥18 years in Kenya to receive ChAdOx1 nCoV-19 or control rabies vaccine, each as a two-dose schedule with a 3-month interval. The co-primary outcomes were safety, and immunogenicity assessed using total IgG enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 spike protein 28 days after the second vaccination. Results Between 28th October 2020 and 19th August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n=200) or rabies vaccine (n=200). Local and systemic adverse events were self-limiting and mild or moderate in nature. Three serious adverse events were reported but these were deemed unrelated to vaccination. The geometric mean anti-spike IgG titres 28 days after second dose vaccination were higher in the ChAdOx1 group (2773 ELISA units [EU], 95% CI 2447, 3142) than in the rabies vaccine group (61 EU, 95% CI 45, 81) and persisted over the 12 months follow-up. We did not identify any symptomatic infections or hospital admissions with respiratory illness and so vaccine efficacy against clinically apparent infection could not be measured. Vaccine efficacy against asymptomatic SARS-CoV-2 infection was 38.4% (95% CI -26.8%, 70.1%; p=0.188). Conclusions The safety, immunogenicity and efficacy against asymptomatic infection of ChAdOx1 nCoV-19 among Kenyan adults was similar to that observed elsewhere in the world, but efficacy against symptomatic infection or severe disease could not be measured in this cohort. Pan-African Clinical Trials Registration PACTR202005681895696 (11/05/2020)
- Open Access
- 31 July 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (7) , e012930
Ethical priorities for international collaborative adaptive platform trials for public health emergencies
- 31 July 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (7) , e012930
Open AccessEthical priorities for international collaborative adaptive platform trials for public health emergencies
- Open Access
- 2 May 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 194
A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies
Background: Public Health Emergencies (PHE) demand expeditious research responses to evaluate new or repurposed therapies and prevention strategies. Alternative Design Trials (ADTs) and Adaptive Platform Trials (APTs) have enabled efficient large-scale testing of biomedical interventions during recent PHEs. Design features of these trials may have implications for engagement and/or informed consent processes. We aimed to rapidly review evidence on engagement and informed consent for ADTs and APTs during PHE to consider what (if any) recommendations can inform practice. Method: In 2022, we searched 8 prominent databases for relevant peer reviewed publications and guidelines for ADTs/APTs in PHE contexts. Articles were selected based on pre-identified inclusion and exclusion criteria. We reviewed protocols and informed consent documents for a sample of large platform trials and consulted with key informants from ADTs/APT trial teams. Data were extracted and summarised using narrative synthesis. Results: Of the 49 articles included, 10 were guidance documents, 14 discussed engagement, 10 discussed informed consent, and 15 discussed both. Included articles addressed ADTs delivered during the West African Ebola epidemic and APTs delivered during COVID-19. PHE clinical research guidance documents highlight the value of ADTs/APTs and the importance of community engagement, but do not provide practice-specific guidance for engagement or informed consent. Engagement and consent practice for ADTs conducted during the West African Ebola epidemic have been well-documented. For COVID-19, engagement and consent practice was described for APTs primarily delivered in high income countries with well-developed health service structures. A key consideration is strong communication of the complexity of trial design in clear, accessible ways. Conclusion: We highlight key considerations for best practice in community engagement and informed consent relevant to ADTs and APTs for PHEs which may helpfully be included in future guidance. Protocol: The review protocol is published online at Prospero on 15/06/2022: registration number CRD42022334170.
- 2 May 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 194
Open AccessA rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies
Background: Public Health Emergencies (PHE) demand expeditious research responses to evaluate new or repurposed therapies and prevention strategies. Alternative Design Trials (ADTs) and Adaptive Platform Trials (APTs) have enabled efficient large-scale testing of biomedical interventions during recent PHEs. Design features of these trials may have implications for engagement and/or informed consent processes. We aimed to rapidly review evidence on engagement and informed consent for ADTs and APTs during PHE to consider what (if any) recommendations can inform practice. Method: In 2022, we searched 8 prominent databases for relevant peer reviewed publications and guidelines for ADTs/APTs in PHE contexts. Articles were selected based on pre-identified inclusion and exclusion criteria. We reviewed protocols and informed consent documents for a sample of large platform trials and consulted with key informants from ADTs/APT trial teams. Data were extracted and summarised using narrative synthesis. Results: Of the 49 articles included, 10 were guidance documents, 14 discussed engagement, 10 discussed informed consent, and 15 discussed both. Included articles addressed ADTs delivered during the West African Ebola epidemic and APTs delivered during COVID-19. PHE clinical research guidance documents highlight the value of ADTs/APTs and the importance of community engagement, but do not provide practice-specific guidance for engagement or informed consent. Engagement and consent practice for ADTs conducted during the West African Ebola epidemic have been well-documented. For COVID-19, engagement and consent practice was described for APTs primarily delivered in high income countries with well-developed health service structures. A key consideration is strong communication of the complexity of trial design in clear, accessible ways. Conclusion: We highlight key considerations for best practice in community engagement and informed consent relevant to ADTs and APTs for PHEs which may helpfully be included in future guidance. Protocol: The review protocol is published online at Prospero on 15/06/2022: registration number CRD42022334170.
- Open Access
- 24 April 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Background: There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind, randomised, controlled trial among adults in Kenya conducted as part of the early studies assessing vaccine performance in different geographical settings to inform Emergency Use Authorisation. Methods: We recruited and randomly assigned (1:1) 400 healthy adults aged ≥18 years in Kenya to receive ChAdOx1 nCoV-19 or control rabies vaccine, each as a two-dose schedule with a 3-month interval. The co-primary outcomes were safety, and immunogenicity assessed using total IgG enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 spike protein 28 days after the second vaccination. Results: Between 28th October 2020 and 19th August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n=200) or rabies vaccine (n=200). Local and systemic adverse events were self-limiting and mild or moderate in nature. Three serious adverse events were reported but these were deemed unrelated to vaccination. The geometric mean anti-spike IgG titres 28 days after second dose vaccination were higher in the ChAdOx1 group (2773 ELISA units [EU], 95% CI 2447, 3142) than in the rabies vaccine group (61 EU, 95% CI 45, 81) and persisted over the 12 months follow-up. We did not identify any symptomatic infections or hospital admissions with respiratory illness and so vaccine efficacy against clinically apparent infection could not be measured. Vaccine efficacy against asymptomatic SARS-CoV-2 infection was 38.4% (95% CI -26.8%, 70.1%; p=0.188). Conclusions: The safety, immunogenicity and efficacy against asymptomatic infection of ChAdOx1 nCoV-19 among Kenyan adults was similar to that observed elsewhere in the world, but efficacy against symptomatic infection or severe disease could not be measured in this cohort. Pan-African Clinical Trials Registration: PACTR202005681895696 (11/05/2020)
- 24 April 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 182
Open AccessSafety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Background: There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind, randomised, controlled trial among adults in Kenya conducted as part of the early studies assessing vaccine performance in different geographical settings to inform Emergency Use Authorisation. Methods: We recruited and randomly assigned (1:1) 400 healthy adults aged ≥18 years in Kenya to receive ChAdOx1 nCoV-19 or control rabies vaccine, each as a two-dose schedule with a 3-month interval. The co-primary outcomes were safety, and immunogenicity assessed using total IgG enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 spike protein 28 days after the second vaccination. Results: Between 28th October 2020 and 19th August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n=200) or rabies vaccine (n=200). Local and systemic adverse events were self-limiting and mild or moderate in nature. Three serious adverse events were reported but these were deemed unrelated to vaccination. The geometric mean anti-spike IgG titres 28 days after second dose vaccination were higher in the ChAdOx1 group (2773 ELISA units [EU], 95% CI 2447, 3142) than in the rabies vaccine group (61 EU, 95% CI 45, 81) and persisted over the 12 months follow-up. We did not identify any symptomatic infections or hospital admissions with respiratory illness and so vaccine efficacy against clinically apparent infection could not be measured. Vaccine efficacy against asymptomatic SARS-CoV-2 infection was 38.4% (95% CI -26.8%, 70.1%; p=0.188). Conclusions: The safety, immunogenicity and efficacy against asymptomatic infection of ChAdOx1 nCoV-19 among Kenyan adults was similar to that observed elsewhere in the world, but efficacy against symptomatic infection or severe disease could not be measured in this cohort. Pan-African Clinical Trials Registration: PACTR202005681895696 (11/05/2020)